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Previous reports have established that vaccinia virus (VV) recombinants expressing G, F, or N protein of
respiratory syncytial (RS) virus protect small animals against intranasal challenge with live RS virus. This
work demonstrates that a variety of parameters affect the protection induced by recombinant viruses. The
route of vaccination, the subtype of challenge virus, and the species used influenced the antibody titers and
extent of protection. During these studies, observations were also made on the subclass of antibody generated,
and pulmonary histopathological changes induced by challenge after vaccination were noted. The effect of route
of inoculation on host response was examined by vaccinating mice intranasally, intraperitoneally, or by
scarification with a recombinant VV expressing the RS virus G glycoprotein. Intranasal vaccination induced
25-fold-higher titers of antibody to RS virus in the lung than the intraperitoneal route did, but both routes
resulted in complete suppression of virus replication after intranasal challenge 21 days after vaccination.
Scarification was a less effective method of vaccination. The antibody induced by recombinant VV in mice was
mostly immunoglobulin G2a (IgG2a) with some IgG2b. No antibody to RS virus was detected in the IgA, IgM,
IgGl, or IgG3 subclass irrespective of the vaccination route. The G and F glycoproteins were shown to elicit
similar subclasses of antibody. However, animals vaccinated with the G and F vectors differed strikingly in
their response to challenge by heterologous virus. Mice or cotton rats vaccinated with recombinant VV carrying
the G gene of RS virus were protected against challenge only with homologous subtype A virus. Vaccination
with a recombinant VV expressing the F glycoprotein induced protection against both homologous and
heterologous subtype B virus challenge. The protection induced in mice was greater than that detected in cotton
rats, indicating that the host may also affect immunity. Finally, this report describes histological examination
of mouse lungs after vaccination and challenge. Vaccinated mice that were subsequently challenged had
significantly greater lung lesion scores than unvaccinated challenged mice. The lesions were primarily
peribronchiolar and perivascular infiltrations of polymorphonuclear cells and lymphocytes. Further work will
establish whether these pulmonary changes are a desirable immune response to virus invasion or a potential
immunopathogenic hazard. The results have important implications for planning a strategy of vaccination
against RS virus and emphasize potential dangers that may attend the use of recombinant VV as vaccines.
Respiratory syncytial (RS) virus was first isolated in 1956
and over 30 years later remains the major cause of hospital-
ization for children in the first year of life in the developed
world. There are two major subtypes of human RS virus,
designated A and B (1). A bovine RS virus (probably related
to group B) is a significant cause of respiratory disease and
mortality in cattle in Europe and the United States. Although
effective live or killed veterinary vaccines are becoming
available for the bovine RS virus (26, 33), there is no
equivalent prophylaxis for children. One of the first vaccines
tested in infants, Formalin-inactivated virus, induced en-
hanced disease when vaccinees were subsequently infected
with RS virus (6, 10, 11, 13). This alarming observation had
a profound effect on research toward safe and effective
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control of RS virus bronchiolitis. Attention turned entirely
toward live attenuated vaccines which were used intranas-
ally or intramuscularly (4, 5, 12, 31, 32). However, this
approach was frustrated by genetic instability or overat-
tenuation of the virus or interference by maternal antibody
with its replication.
Three theories have been advanced to explain enhanced
disease. First, that serum antibody in the absence of nasal
antibody was immunopathogenic. Second, that Formalin
induced altered reactivity to the killed virus. Finally, that the
inactivated vaccine caused delayed hypersensitivity. Al-
though recent evidence (19) suggested that formaldehyde
damaged the RS virus fusion protein antigen so that the
vaccine induced antibody with reduced biological activity,
this is by no means established and may not be the whole
explanation of vaccine-enhanced disease. There is, there-
fore, a need to distinguish protective responses to RS virus
from those which are potentially pathogenic.
Recombinant vaccinia viruses (VV) carrying genes for RS
virus proteins have recently been shown to protect cotton
rats and mice against intranasal challenge with RS virus (9,
14, 20, 25, 30). Such recombinant viruses are powerful tools
with which the immune response to individual RS virus
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antigens may be dissected. For example, using recombinant
vectors, the surface glycoproteins, G and F, have been
shown to induce high titers of humoral antibody which
correlate with protection of lungs from live virus challenge
(2, 9, 20, 25, 30). In addition, the internal nucleocapsid gene
of RS virus has been identified as a significant target for the
cell-mediated immune response (3). These initial studies
have provided useful insight into the roles of individual viral
proteins in the infection process. However, many aspects of
the response to vaccination with these vectors require char-
acterization.
In an effort to understand how expression of individual RS
virus proteins might be providing a protective effect against
RS virus or participating in the potentiation of disease, we
analyzed the following parameters of vaccination with
recombinant vectors bearing RS virus genes: (i) route of
inoculation, (ii) class of antibody produced in lung and serum
as a function of route of administration, (iii) effect of species
of test animal on protection level, and (iv) cross subgroup
protection in relation to the surface glycoproteins.
In addition to the above studies we also carried out
histopathological analyses of lung sections after vaccination
and challenge. These studies were aimed at determining
whether a particular RS virus protein might be involved in
potentiating disease.
MATERIALS AND METHODS
Viruses. The Australian A2 strain (16) belongs to RS virus
subtype A, and the 8/60 strain (8) belongs to subtype B (1).
Both viruses were grown and titrated on HEp-2 cells. The
overlay for plaque assay consisted of Eagle minimal essen-
tial medium supplemented with 10% fetal calf serum, 20 ,ug
of bromodeoxyuridine per ml, 25 mM HEPES (N-2-hy-
droxyethylpiperazine-N'-2-ethanesulfonic acid) (pH 7.6),
and 0.25% agarose. Plates were incubated for 7 days at 37°C.
The construction and characteristics of the recombinant
VV vG301, containing the large glycoprotein (G) gene,
vF325 and vF317, containing the fusion protein (F) gene, and
vN125 and vN333, containing the nucleoprotein (N) gene,
have been described previously (2, 14, 30). Briefly, cDNAs
of the RS virus genes were inserted into the EcoRI site of the
VV thymidine kinase gene, downstream from the initiation
site for transcription of the VV 7.5K promoter. A recombi-
nant vector containing the gene for the nonstructural protein
1B was made by similar methods. Details of its construction
will be reported elsewhere (K. Anderson, L. A. Ball, and G.
Wertz, manuscript in preparation). Recombinant VV were
grown and assayed on HEp-2 cells. Infected cell lysates
were sonicated for 2 min and centrifuged at 1,000 x g for 5
min, and the supernatant was layered over 35% sucrose in 10
mM Tris hydrochloride, pH 8.8. After centrifuging at 18,000
rpm in an SW27 rotor for 80 min at 4°C, the pelleted virus
was resuspended in 1 ml of 10 mM Tris hydrochloride, pH
8.8. This material was stored at -70°C and diluted in 10 mM
Tris hydrochloride (pH 8.8) before inoculation into animals.
Animals. Male BALB/c ByJ mice free from infection with
Sendai virus, pneumonia virus of mice, and Mycoplasma
pulmonis were obtained from Jackson Laboratory (Bar
Harbor, Maine) at 4 weeks of age. Cotton rats (Sigmodon
hispidus) 8 to 12 weeks old were supplied by W. Clyde from
a colony maintained by the University of North Carolina. All
experiments were based on groups of at least five animals.
Vaccination and challenge. Unanesthetized mice were vac-
cinated with 100 ,ul by intraperitoneal injection or with 10 j.al
by scarification of the tail with a bifurcated needle.
Intranasal vaccine in 50 ,u1 was instilled into the noses of
mice anesthetized with 2 mg of sodium pentobarbital in-
jected intraperitoneally. Cotton rats were anesthetized by
inhalation of methoxyflurane (Abbott Laboratories, North
Chicago, Ill.) before intradermal injection of 100 ,u1 of
vaccine. Animals were challenged under anesthesia as de-
scribed above by intranasal instillation of 50 p.l (mice) or 100
,ul (cotton rats) of phosphate-buffered saline containing 104.2
to 105 PFU of RS virus.
Antibody assay. Live mice were bled from the tail vein.
After animals were killed with an overdose of sodium
pentobarbital, blood was collected from the axilla or heart.
Mouse lungs were washed by tying a 20-gauge cannula into
the trachea and inflating and deflating the lungs twice with 1
ml of phosphate-buffered saline. Antibody to RS virus in
sera and lung washings was assayed by enzyme-linked
immunosorbent assay (ELISA). Microtiter plates (Falcon;
Becton Dickinson Labware, Oxnard, Calif.) were coated
with RS virus-infected HEp-2 cell lysate or uninfected cell
lysate as a control and dried overnight at 37°C. After
incubation with blocking buffer (phosphate-buffered saline
containing 0.05% Tween 20 and 5% pig serum) for 30 min at
22°C, the plates were washed thoroughly in phosphate-
buffered saline containing 0.05% Tween 20. Dilutions of sera
or lung washings were added and incubated for 60 min at
22°C. After further washing, bound antibody was detected
by adding goat anti-mouse immunoglobulin G (IgG) serum
coupled to horseradish peroxidase (Kirkegaard and Perry
Laboratories Inc., Gaithersburg, Md.) or horseradish perox-
idase-conjugated rabbit anti-mouse IgM, IgA, IgGl, IgG2a,
IgG2b, or IgG3 (Miles Scientific, Div. Miles Laboratories,
Inc., Naperville, Ill.). After further washing, 3,3',5,5'-
tetramethylbenzidine and hydrogen peroxide in 0.1 M citrate
buffer (pH 5.0) were added as substrates. The reaction was
stopped by the addition of 0.1 M sulfuric acid, and the
optical density (OD) was read at 450 nm. ELISA titers were
calculated after subtraction of OD with control antigen from
OD with virus-infected antigen and plotting this specific OD
against sample dilution. By regression analysis of the linear
part of this curve, the endpoint was deduced at an OD 1.5
times the background.
Virus assay. Lungs were weighed and ground in Hanks
balanced salt solution containing 0.218 M sucrose, 4.8 mM
glutamate, 30 mM magnesium chloride, 25 mM HEPES
buffer, 200 U of penicillin per ml, and 200 ,ug of streptomycin
per ml to give a 10% suspension. After centrifugation at
10,000 x g for 2 min, the supernatant fluid was assayed in
HEp-2 cells as described above.
Histology. Lungs were inflated with and then immersed in
fixative consisting of 10% formaldehyde in saturated mercu-
ric chloride. Sections of lung were stained with hematoxylin
and eosin and examined for abnormal pathology (lesions).
Coded sections of lung were scored for lesions by an
arbitrary scale of 0 to 3, with 1 representing infiltration
involving one or two bronchioles or blood vessels and 3
representing lesions involving most of the bronchioles and
blood vessels. A minimum of three lobes were examined and
scored for each mouse so that the mean lesion score for each
group was based on at least 15 observations.
RESULTS
Route of vaccination. To determine the effect of route of
administration of vaccine on antibody levels stimulated in
serum and lung and on protection, we inoculated groups of
mice with 2 x 106 PFU of vG301 by one of the following
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FIG. 1. Effect of vaccination route on ELISA antibody response
to RS virus. Symbols: 40- -4-, intranasal; 0-4, intraperitoneal;
*----, scarification. Arrow indicates intranasal challenge with RS
virus.
routes: (i) intraperitoneal, (ii) intranasal, or (iii) scarification
of the tail. Seven days later, the mean serum antibody titer to
RS virus was 2.9 log1o in mice vaccinated intraperitoneally
(Fig. 1). Antibody was not detected in animals vaccinated
intranasally or by scarification until 14 days. Three weeks
after vaccination mice were challenged intranasally with RS
virus. At this time the titer of serum antibody in scarified
mice was at least fivefold lower than that in the other two
vaccinated groups (Fig. 1; Table 1). Antibody titers in lung
washings were highest (102.2) in mice vaccinated intranasally
and lowest (<100°5) in scarified mice. Five days after
challenge, the mean titer of RS virus in lungs of unvac-
cinated mice was 4.8 log1o PFU/g. In contrast, no virus was
recovered from mice vaccinated intraperitoneally or intra-
nasally. Virus was recovered from two of five mice vacci-
nated by scarification giving a mean titer of 1.6 log1o PFU/g.
Seven days after challenge, antibody titers in serum were 3-
to 50-fold greater than at day 21. During the same period,
titers of antibody in the lung rose by 1,000-fold or more in
mice vaccinated intraperitoneally or by scarification, but by
only 5-fold in mice vaccinated intranasally.
Antibody class. The isotype of antibody to RS virus was
determined by ELISA before (day 21) and after (day 28)
challenge (Table 2). Antibody in both serum and lung wash-
ings was predominantly IgG2a and IgG2b. At day 21, the
route of administration had little or no effect on distribution
of antibody isotype in serum. In the lung, however, measur-
able IgG2a and IgG2b antibody was detected only after
intranasal vaccination. At 28 days postvaccination, signifi-
cant titers of antibody were present in serum of animals
vaccinated by all these methods, although titers in animals
vaccinated by intraperitoneal inoculation were significantly
higher for both the IgG2a and IgG2b classes. No antibody to
RS virus was detected in the IgA, IgM, IgGl, or IgG3
subclasses.
The data on antibody isotype generated above used a
recombinant expressing the RS virus glycoprotein (G) as the
antigenic stimulus. The G protein is an unusual viral mem-
brane protein. G is estimated to have 50 to 60% of its 84,000
molecular weight contributed by carbohydrate, the majority
of which is tunicamycin resistant, thereby suggesting that it
is 0- rather than N-linked. It was of interest, therefore, to
determine whether the antibody isotype distribution would
differ if a recombinant expressing the second RS virus
surface protein F, the fusion protein, was used for vaccina-
tion. The F protein has only five carbohydrate attachment
sites, and all are tunicamycin sensitive, indicating that they
are N-linked. The antibody induced by vaccination in mice
with vF325 was predominantly of the IgG2a type with some
IgG2b (data not shown). This pattern is analogous to that
observed after vaccination with the G-expressing vector.
Also, as with the G vaccination, no antibody of the IgA,
IgM, IgGl, or IgG3 subclass was detected.
Effect of heterologous challenge. There are at least two
major subtypes (A and B) of human RS virus, and analyses
with monoclonal and polyclonal antibodies indicate that the
major difference between these subtypes resides in the G
glycoprotein. We therefore investigated the degree of cross
protection that the glycoproteins G or F might elicit against
the two major subtypes of RS virus. Mice were vaccinated
intraperitoneally with recombinants expressing either the G
gene or the F gene of the subgroup A virus (A2 strain) and
challenged 3 weeks later with either A2 strain or 8/60 strain
(B subtype) RS virus (Table 3). At the time of challenge
antibody titers to A2 virus were 3.9 to 4.0 log1o. Although
mice given vF325 vaccine had similar titers against 8/60 virus
(4.1 log1o), antibody titers of animals given vG301 vaccine
were 40-fold lower against 8/60 (Table 3). Despite the fact
that the 8/60 B-type RS virus only grows to low titers in
mice, i.e., 2.9 log1o PFU/g of lung (see below for compara-
tive growth in cotton rats), differences in the response to
challenge were detected which reflected the observed differ-
ences in antibody levels. Mice vaccinated with vG301 or
TABLE 1. Effect of route of vaccination on antibody production and protection
Day 21 antibody titer Day 28 antibody titer
Vaccinea Route of at challengeb Day 26 virus titer after challenged
vaccination after challenge'
Serum Lung Serum Lung
vG301 Intraperitoneal 3.8 ± 0.4 0.8 ± 0.5 <1.5 4.4 + 0.2 3.8 ± 0.4
vG301 Intranasal 3.9 ± 0.1 2.2 ± 0.2 <1.5 4.4 ± 0.3 2.9 ± 0.2
vG301 Scarification 3.1 ± 0.2 <0.5 1.6 ± 0.2 4.7 ± 0.4 3.5 ± 0.5
None <1.5 <0.5 4.8 ± 0.1 1.6 ± 0.3 <0.5
a All vaccines were inoculated at a dose of 2 x 106 PFU.
b Antibody titers were measured by ELISA and are expressed as mean loglo ± standard error. Mice were challenged intranasally with 104.2 PFU of RS virus
21 days after vaccination.
c Virus titers are expressed as mean log1o PFU per gram ± standard error. Mice were killed for virus titration 5 days after challenge.
d Antibody was assayed 7 days after challenge.
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TABLE 2. Immunoglobulin subclass of antibody to RS virus0
Antibody titers on day 21 Antibody titers on day 28
Vaccine Route of Serum Lung Serum Lungvaccination
IgG2a IgG2b IgG2a IgG2b IgG2a IgG2b IgG2a IgG2b
vG301 Intraperitoneal 1.7 ± 0.5 <1.0 <0.3 <0.3 3.4 ± 0.4 3.1 ± 0.4 1.6 ± 0.3 0.6 ± 0.5
vG301 Intranasal 1.7 ± 0.3 1.3 ± 0.3 1.4 ± 0.4 0.6 ± 0.3 2.3 ± 0.5 2.0 ± 0.7 1.1 ± 0.5 0.4 ± 0.2
vG301 Scarification 1.3 ± 0.2 1.1 ± 0.6 <0.3 <0.3 2.1 ± 0.7 1.8 ± 0.5 2.1 ± 0.5 0.4 ± 0.3
None <1.0 <1.0 <0.3 <0.3 <1.0 <1.0 <0.3 <0.3
a Antibody titers were measured by ELISA and are expressed as mean logi0 ± standard error.
vF325 had no detectable virus in the lungs 5 days after
challenge with the homologous A2 virus. In contrast, only
the lungs of mice vaccinated with vF325 were free of virus
after challenge with the heterologous 8/60 (B-type) virus.
There was no significant difference between mean 8/60 virus
titers in the lungs of unvaccinated mice and those given
vG301 vaccine (Table 3).
Effect of species. There are two major small animal model
systems for human RS virus, the BALB/c mouse and the
cotton rat (S. hispidus). To compare the results obtained in
mice with those from an alternative animal model of a
different species, we examined the effectiveness of vaccina-
tion in cotton rats against A and B subtype viruses with that
described above in mice. Cotton rats were vaccinated with
recombinants containing the G or F gene and challenged
with A2 or 8/60 virus (Table 4). In animals given the vG301
vaccine, no virus was detected in the lungs of two of five rats
challenged with the A2 virus and the mean virus titer was
significantly reduced (from 5.6 log1o to 3.5 log1o). There was
no protection against the 8/60 B-type challenge virus, and the
reduction of 0.4 log1o in virus titer was not statistically
significant. No virus was recovered from the lungs of six of
seven of the rats vaccinated with vF317 and challenged with
A2 and four of five rats challenged with 8/60 virus. The mean
virus titer was reduced by 3.8 or 2.8 log1o after challenge
with A2 or 8/60 virus, respectively. The results obtained in
cotton rats are consistent with those obtained in mice.
However, the reduction in virus titer in the lungs of the
cotton rats was more variable. This might be due to the fact
that whereas the mice are inbred, the rats are not, or that the
interdermal inoculation of the cotton rats is less reproducible
(Tables 1, 3, and 4).
Effect of vaccination on lung lesions. The effect of vaccina-
tion and challenge on the histology of the lung was also
examined. In the absence of RS virus challenge, vaccination
by scarification or intraperitoneal injection had no significant
effect on the lungs when compared with those of untreated
mice (Table 5; P = 0.45 or 0.93, respectively). In contrast, 21
days after intranasal vaccination the lesion score was 0.74
compared with 0.01 in unvaccinated animals, a highly signif-
icant difference (P = 0.0001). The lesions in the intranasally
vaccinated mice at this time showed peribronchiolar and
perivascular accumulations of lymphocytes and macro-
phages. In some areas, the bronchiolar epithelial cells were
proliferating, and in others the epithelial cells were elongated
and flattened. The epithelial lining was infiltrated with mono-
nuclear cells, and there were a few mononuclear cells and
desquamated epithelial cells in the lumen. However, the
bronchiolar exudate was minimal, and this may be due to the
lung lavage performed before fixation. In some areas of the
lung parenchyma there was thickening of the alveolar walls
owing to mononuclear cell infiltration, and the alveoli con-
tained large foamy macrophages.
After challenge, the lesion score of the intranasally vacci-
nated mice did not change; however, the lesions, although
similar to those described above, showed a greater predom-
inance of lymphocytes in the peribronchiolar and perivas-
cular cell accumulations and fewer areas of epithelial cell
proliferation. The epithelial cells were still enlarged, but
there was less infiltration with mononuclear cells.
After RS virus challenge, the lesion scores of unvac-
cinated mice and of those vaccinated intraperitoneally or by
scarification were significantly greater than those of unchal-
lenged mice (Table 5; P = 0.003 to 0.024). Furthermore,
lesions in mice vaccinated intraperitoneally or by scarifica-
tion were significantly greater than those due to RS virus
alone (P = 0.05 and 0.029, respectively). The lesions in
unvaccinated mice have been described in detail elsewhere
(29) and are composed of slight peribronchiolar and peri-
vascular accumulations of lymphocytes with polymorpho-
nuclear leukocytes and enlargement of the bronchiolar epi-
thelial cells and occasional areas where the alveolar walls are
thickened. The lesions in the vaccinated mice were essen-
tially the same but with increased peribronchiolar and
perivascular accumulations and greater infiltration of the
alveoli with lymphocytes and macrophages.
As described above, mice given recombinant vG301 had
increased lesion scores after challenge (Table 5). To estab-
lish whether VV recombinants containing other RS virus
genes induced the same effect, the lungs of mice given
TABLE 3. Effect of heterologous challenge
Route of Dose Day 21 antibody titera Day 26 virusVaccine vciain10PF)Challenge viruSb Daye 26 viunSrvaccin tion(10~~~ PFU) A2 8/60tieinlgs
vG301 Intraperitoneal 1 3.9 + 0.2 2.3 ± 0.4 A2 <1.7
8/60 2.2 ± 0.4
vF325 Intraperitoneal 2 4.0 ± 0.4 4.1 ± 0.4 A2 <1.7
8/60 <1.7
None <1.5 <1.5 A2 4.4 ± 0.2
8/60 2.9 ± 0.1
a Antibody titers were measured by ELISA and are expressed as mean loglo ± standard error.
b Mice were challenged intranasally with 104.2 PFU of either the A2 or 8/60 strain of RS virus 21 days after vaccination.
c Virus titers expressed as mean logl0 PFU per gram ± standard error. Mice were killed for virus titration 5 days after challenge.
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TABLE 4. Protection of cotton rats by recombinant VV
Vaccine Route of Dose Day 21 Challenge No. protected/ Virus titer Difference (P)vaccination (107 PFU) antibody titer"' (PFU) no. challenged in lung'
vG301 Intradermal 9 3.3 ± 0.6 A2 (5 x 104) 2/5 3.5 ± 1.7 0.05
8/60 (1 x 105) 0/5 4.2 ± 0.4 0.07
vF317 Intradermal 5 3.0 ± 0.5 A2 (5 x 104 ) 6/7 1.8 ± 0.4 <0.0001
8/60 (1 x 105) 4/5 1.8 ± 0.7 0.001
None <1.5 A2 (5 x 104) 0/7 5.6 ± 0.2
8/60 (1 x 105) 0/5 4.6 + 0.2
aAntibody titers were measured by ELISA against A2 virus and are expressed as mean logl0 + standard error.
I Virus titers are expressed as mean loglo PFU per gram ± standard error.
C Probability of differences from unvaccinated mice were calculated by Student's t test.
vF325, vN125, or vlB were examined 7 days after RS virus
challenge (Table 6). Both recombinants vF325 and vN125
induced significantly increased lesion scores 7 days after
challenge compared with unvaccinated mice (P = 0.015 and
0.017, respectively). The lesions were similar to those de-
scribed above for mice vaccinated intraperitoneally with
vG301. However, the lesion score of mice given vlB was not
significantly greater than that in unvaccinated mice (P =
0.81). This latter observation demonstrated that the vaccinia
vector itself is not responsible for the increase in scores in
vaccinated animals.
DISCUSSION
Recombinant VV expressing foreign genes have been
proposed as potential vaccines. Before this approach can be
feasible, extensive studies of the biological properties of
these viruses in various animal models must be undertaken.
Vaccinations with recombinant viruses expressing the G, F,
or N protein of RS virus abolish or significantly reduce the
titer of virus in the lung after intranasal infection (14, 25, 30)
and thus provide a system in which recombinant-induced
immunity to this respiratory pathogen may be analyzed.
One of the most important variables affecting antibody
level and extent of protection in mice was the route of
vaccination. Intranasal vaccination induced 25-fold-higher
titers of antibody in the lung than either of the parenteral
routes. Despite this difference, after challenge there was no
detectable virus in the lungs of animals vaccinated by either
intranasal or intraperitoneal routes. Part of the explanation
for this immunity is probably that the appearance in the lung
of RS virus antigen, with or without limited replication,
stimulated the localization of large numbers of sensitized
lymphocytes and a consequent local production of large
amounts of protective antibody. Support for this hypothesis
is provided by the histological finding of peribronchiolar
infiltration of lymphocytes (Table 5; discussed below) and
the large increases in antibody in the lung 7 days after
challenge (Table 1). The high levels of antibody are sufficient
to explain the protection observed since it is known that
passive transfer of monoclonal antibodies to G glycoprotein
protects mice (28). It is unlikely that cytotoxic T cells played
a significant role in the protection induced by this recombi-
nant because vG301 does not stimulate cytotoxic T-cell
memory (3). The relatively poor response to vaccination by
scarification may be a reflection of the difficulty of determin-
ing the exact dose absorbed. Although 2 x 106 PFU were
applied to the skin, only a small proportion may have
initiated infection. A similar marked dependence of immune
response on route of vaccination has been reported by Small
and colleagues (24), who showed that intradermal vaccina-
tion of mice with a recombinant VV containing the H-2
influenza virus hemagglutinin gene protected only the lower
respiratory tract, whereas intranasal vaccination protected
both nose and lung from infection. A further consideration
highlighted by our experiments is that of safety. We have
already shown that wild-type VV given intranasally is lethal
to mice (25), but it is now clear that although mice remained
clinically normal after intranasal vaccination with recombi-
nant vG301, significant lesions were present in their lungs
over 3 weeks after vaccination (Table 5). Thus, although
intranasal vaccination may seem a logical route for protec-
tion against a respiratory infection, it may be neither neces-
sary nor desirable if the primary objective is to protect the
lower respiratory tract.
Our observations that antibody responses to both vG301
and vF325 were predominantly in the IgG2a subclass with
some IgG2b were consistent with the finding that the re-
sponse of mice to infection by a variety of other respiratory
and enteric viruses is restricted to the IgG2a subclass with
some activity in the IgG2b subclass but relatively little in
IgGl or IgG3 (7). Furthermore, we are confident that the
sensitivity of the assays used here was adequate to have
detected the other antibody classes since similar assays on
mice after infection with M. pulmonis demonstrated specific
TABLE 5. Effect of route of vaccination on lung lesions before and after challenge
VaccineaRoute of Lung lesion scoreb
vaccination Before challenge p1c After challenge pl p2d
vG301 Intraperitoneal 0.01 ± 0.02 0.93 0.41 + 0.13 0.05 0.008
vG301 Intranasal 0.74 ± 0.09 0.0001 0.74 ± 0.08 0.0001 0.97
vG301 Scarification 0.02 + 0.03 0.45 0.43 ± 0.14 0.029 0.003
None 0.01 ± 0.02 0.22 ± 0.08 0.024
a The dose of vaccine was 2 x 106 PFU.
bMean ± standard deviation 21 days after vaccination (before challenge) or 28 days after vaccination (after challenge).
C pl, Probability of differences between vaccinated groups and control calculated by Student's t test.
d p2, Probability of differences between challenged and unchallenged mice calculated by Student's t test.
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TABLE 6. Effect of vaccine on lung lesions
Vaccine Route of Dose Challenge Antibody Lesion score Difference (p)bvaccination (107 PFU) Calnetitera
vF325 Intraperitoneal 2 A2 4.0 ± 0.4 0.53 ± 0.14 0.015
vN125 Intraperitoneal 1 A2 3.4 ± 0.2 0.26 ± 0.02 0.017
vlB Intraperitoneal 2 A2 <1.5 0.18 ± 0.03 0.81
None A2 <1.5 0.16 ± 0.05
None None <1.5 0.08 ± 0.10
a Antibody titer was measured by ELISA 28 days after vaccination and is expressed as mean ± standard error.
b Probability of differences between vaccinated and unvaccinated groups was calculated by Student's t test.
antibody in immunoglobulin subclasses IgGl, IgG2, IgA,
and IgM in both sera and lung washes (27). Murine antibody
responses to soluble proteins and carbohydrates are gener-
ally restricted to the IgGl and IgG3 subclasses, respectively
(17, 21, 23). The fact that no antibody to RS virus G
glycoprotein was found in the IgG3 subclass suggests that
although approximately 60% of its mass is carbohydrate (2),
this moiety does not make a significant contribution to its
antigenicity, at least in mice. The IgGl and IgG2 subclasses
differ in their ability to activate mouse complement (15) and
possibly in their ability to effect antibody-dependent cell
cytotoxicity. Thus, the IgG2a restriction of the response to
recombinant VV may be a significant aspect of the protec-
tion they afford in mice and has important implications for
vaccine strategy.
There are at least two subgroups of RS viruses which are
distinguished by monoclonal and polyclonal antibodies to F
and G proteins (1, 18, 28). We therefore challenged mice
vaccinated with recombinants containing the F or G gene
from A2 virus, a subtype A virus, with representative strains
of A and B subtypes. Although vaccination with the F
protein vectors protected against both subtype A and B
virus, the G protein vectors only reduced replication of the
homologous virus. This observation is consistent with re-
sults from the passive transfer of monoclonal antibodies.
Monoclonal antibodies against F protein which protect also
cross-react with both A and B subtype viruses. In contrast,
protective antibodies specific for G of subtype A fail to react
with viruses of subtype B (28). Few monoclonal antibodies
to G cross-react between the subtypes, indicating that there
are few shared epitopes (1, 18, 28). This is probably the
explanation for the low antibody reaction to 8/60 virus in
mice given vG301. Thus, in considering the components
desirable in an effective vaccine it is apparent that vaccina-
tion with F protects against both heterologous and homolo-
gous virus in mice but that G antigens of both subtypes will
be necessary for maximum efficacy.
In the original reports of recombinant VV containing G
and F genes, differences in the level of immunity induced
were apparent (9, 20, 25, 29). It was unclear whether these
discrepancies were due to differences between the recombi-
nants used, the routes of vaccination, or the species in-
volved. The levels of protection we observed in cotton rats
given vG301 and vF317 are similar to those reported by
Olmstead and colleagues (20) using different recombinants
carrying F and G genes, indicating that the potency of the
different recombinants is similar in terms of the protection
they induce. It is clear from the present investigation that
intradermal vaccination is less efficient than other routes
(Table 1). However, even by this route the reduction in RS
virus in the lung was 10-fold greater in mice (103.2 PFU) than
in cotton rats (102.1 PFU), although the dose of vG301 given
to the rats was 45-fold higher. Greater efficacy in mice may
be related to the mouse adaptation of the WR strain of
vaccinia which was the parent of the recombinant viruses.
A further difference between the mouse and cotton rat
model systems is highlighted by the work reported here. In
mice, vaccination with recombinant VV carrying either the
G or F gene resulted in no detectable virus in the lungs after
challenge with homologous virus. However, recombinants
carrying the F gene protected cotton rats more effectively
than those containing the G gene (Table 4). This latter
observation was also made by Olmstead et al. (20). In view
of these differences between the species it is important to
test these recombinant VV in larger animals, such as chim-
panzees, or to test protection against the bovine RS virus in
its natural host, cattle.
Histological examination of the lungs of animals vacci-
nated with the recombinant VV and challenged with RS
virus has not previously been reported and is especially
relevant for RS virus for which prior vaccination has been
reported to cause enhanced disease upon challenge. We
have reported that intranasal inoculation of mice with wild-
type WR strain VV caused severe clinical disease but that no
overt disease followed intranasal vaccination with thymidine
kinase-negative recombinant VV (25). It was, therefore,
important to note extensive histopathological changes in
lungs of mice 21 days after intranasal infection with vG301
(Table 5). Since this infiltration was not seen in mice
vaccinated by parenteral routes it was probably due to local
replication of virus in the respiratory tract. Of even greater
concern was the significant increase in lesion score after
vaccination with vG301, vF325, or vN125 followed by
intranasal challenge with RS virus (Tables 5 and 6). Since the
VV was purified and no such enhanced lesions were ob-
served after vaccination with a recombinant containing the
1B gene of RS virus and subsequent challenge (Table 6) it is
unlikely that they were caused by the VV vectors or host-
derived components associated with them. Similar increased
infiltration occurred after vaccination of cotton rats with
Formalin-inactivated RS virus and subsequent intranasal
challenge (22). However, after Formalin-inactivated virus
the infiltration was predominantly neutrophils, whereas in
the present work lymphocytes predominated. In view of the
relevance of these observations to the safety of RS virus
vaccines, it is now important to establish whether these
pulmonary responses are part of a normal and desirable
immune response to virus invasion or whether they present
a potential immunopathogenic hazard. Work is therefore in
progress to identify the type and function of the cells
infiltrating the lungs.
The present work illustrated the value of recombinant VV
as tools with which to investigate immunity to RS virus.
However, dangers have been highlighted which demand
caution in considering these viruses as potential vaccines in
animals or in humans.
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